Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07226349 · ClinicalTrials.gov registry record · Phase 1

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
105
Enrollment target
13
Study locations

NCT07226349 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 105 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (45% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07226349, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
105 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Fulvestrant
  • DRUG BGB-43395
  • DRUG BG-75098

Study Locations (13)

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Houston - Houston

Victoria

  • Cabrini Hospital Malvern - Malvern East
  • Peter Maccallum Cancer Centre - Melbourne

Hubei

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology - Wuhan
  • Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch - Wuhan

Shandong

  • Qilu Hospital of Shandong University - Jinan
  • Weifang Peoples Hospital - Weifang

Alabama

  • University of Alabama At Birmingham Hospital - Birmingham

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown

Queensland

  • Icon Cancer Centre Wesley - Auchenflower

Guangdong

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) - Guangzhou

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2025-12-11
Est. Completion 2029-03-15
Phase Phase 1

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07226349

The ClinicalTrials.gov registry entry for NCT07226349 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (45% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.

NCT07226349 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Texas, Victoria, Hubei.

Frequently Asked Questions

What is clinical trial NCT07226349 about?

NCT07226349 is a clinical study titled "A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors". The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

What is the current status of trial NCT07226349?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2025-12-11. Estimated completion is 2029-03-15.

What conditions does trial NCT07226349 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07226349?

The interventions under investigation include: Fulvestrant (DRUG), BGB-43395 (DRUG), BG-75098 (DRUG).

Who is sponsoring clinical trial NCT07226349?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07226349 being conducted?

This trial has 13 study locations across Alabama, Texas, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.